Tyra Biosciences (TYRA) Cash & Equivalents (2020 - 2026)

Tyra Biosciences (TYRA) has 7 years of Cash & Equivalents data on file, last reported at $85.0 million in Q1 2026.

• Quarterly Cash & Equivalents fell 15.65% year-over-year to $85.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $85.0 million (down 15.65% YoY) and the FY2025 annual result came in at $77.4 million, down 15.85% from the prior year.
• Cash & Equivalents grew to $85.0 million in Q1 2026, from $77.4 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $292.5 million in Q1 2022 to a low of $58.0 million in Q4 2023.
• A 5-year average of $164.9 million and a median of $103.9 million in 2024 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2022 — Cash & Equivalents soared 107.98% — and 2023, when it plunged 76.91%.
• Tracing TYRA's Cash & Equivalents over 5 years: stood at $251.2 million in 2022, then sank by 76.91% to $58.0 million in 2023, then soared by 58.55% to $92.0 million in 2024, then decreased by 15.85% to $77.4 million in 2025, then increased by 9.78% to $85.0 million in 2026.
• The last three Cash & Equivalents figures came in at $85.0 million (Q1 2026), $77.4 million (Q4 2025), and $62.0 million (Q3 2025), per Business Quant data.